UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
1. URGN downgraded from Buy to Neutral by HC Wainwright analyst. 2. FDA committee voted against UGN-102's benefit-risk profile. 3. Timely approval likelihood for UGN-102 is now significantly lowered. 4. URGN's financial position remains stable with $200 million cash. 5. Next-generation candidates UGN-103 and UGN-104 are in development.